Impact of the COVID-19 pandemic on therapeutic management of rheumatoid arthritis in Brittany (France) - 05/06/21
Doi : 10.1016/j.jbspin.2021.105179
Baptiste Queré a, Alain Saraux b, Thierry Marhadour a, Sandrine Jousse-Joulin a, Divi Cornec c, Camille Houssais a, Guillermo Carvajal Alegria c, Maxime Quiviger a, Margot Le Guillou a, Valérie Devauchelle-Pensec c, Dewi Guellec d, ⁎ 
a Rheumatology department, CHU de Brest, Brest, France
b Rheumatology department, CHU de Brest, University of Brest, Inserm, UMR1227, Lymphocytes B et autoimmunité, University of Brest, Inserm, LabEx IGO, Brest, France
c Rheumatology department, CHU de Brest, University of Brest, Inserm, UMR1227, Lymphocytes B et autoimmunité, Brest, France
d Rheumatology department, CHU de Brest, Inserm, CIC 1412, Brest, France
⁎Corresponding author.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Highlights |
• | This is the first study that looks at the impact of the COVID-19 pandemic on RA therapeutic management in France. |
• | This study shows that the optimal DMARD treatment was impacted by the pandemic in around 10% of RA patients. |
• | In most cases, treatment modification was the consequence of a patient's decision rather than a decision driven by a healthcare professional. |
Esquema
© 2021
Société française de rhumatologie. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 88 - N° 4
Artículo 105179- juillet 2021 Regresar al número
Artículo precedente
- Time trends in in-hospital mortality reduction in vasculitis vs. non-vasculitis hospitalisations vary by patient sex and age
- Jasvinder A. Singh
- Serum trough levels of adalimumab correlate inversely with disease activity in patients with inflammatory arthritis
- Peter K.K. Wong, Alison Bowling, Hanish Bagga, Demi Giammichele, Peter Hobson, Daman Langguth
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.